Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study

Wolff, Marcelo; Charpentier, Paulo; Canals, Andrea; Vial, Cecilia; Hormazábal, Juan; Cortés, Jimena; Silva, Macarena

doi:10.1016/j.vaccine.2023.12.035

Vaccine

2024

DOI: 10.1016/j.vaccine.2023.12.035

|View full text |Cite

Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study

Marcelo Wolff,

Paulo Charpentier,

Andrea Canals

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies, including ours, indeed described weaker immune response to COVID-19 vaccines in PWH with low CD4 T cell numbers, with the highest impact on neutralizing levels and waning observed in PWH with less than 200 CD4 T cells/μL. [8][9][10][11] Together with the absence of PWH showing low CD4 + T cell count, the limited number of individuals tested represents a limitation of the present study. Further studies on larger population of individuals and on immunocompromised patients are needed to monitor the efficacy of the vaccination campaign.…”

mentioning

confidence: 55%

JN.1 neutralizing antibody titers after XBB.1.5 monovalent vaccine boost in healthcare workers and people with HIV

Matusali,

Mazzotta,

Meschi

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

Winter 2023-2024 COVID-19 vaccine campaign will rely on the updated XBB.1.5-monovalent boost (with Moderna's mRNA-1273.815, Pfizer/ BioNtech's raxtozinameran, and Novavax' NVX-COV2601 having been recently approved). The in vitro efficacy of such vaccines against BA.2.86 has been demonstrated. 1,2 On November 22, 2023, WHO escalated BA.2.86 to a variant of interest (VOI) and on December 19, 2023 the direct descendant JN.1 was also classified as a separate VOI due to its rapid spread worldwide. The JN.1 VOI harbours the immune-escape Spike mutations L455F, 3,4 similarly to the L455F in "FLip" sublineages. 5,6 We report here JN.1-neutralizing antibody (nAb) titers in 14 healthcare workers (HCW) and 11 people with HIV (PWH) attending the National Institute for Infectious Diseases Lazzaro Spallanzani in Rome who received a dose of the updated messenger RNA (mRNA) monovalent vaccine (raxtozinameran) in October 2023. Samples were collected on the day of vaccination (T0) and 1 month later (T1) (median 31 days, interquartile range [IQR]: 29-35) after the raxtozinameran vaccine. Live authentic JN.1 and XBB.1.16 cultured on Vero E6 cells were used for the micro-neutralization assays. The highest serum dilution inhibiting at least LETTER TO THE EDITOR Committee of the Lazzaro Spallanzani Institute (approval number: 423/2021; amendment adopted with no. 91/2022). The participants included in the present study provided informed written consent.

show abstract

mentioning

confidence: 55%

JN.1 neutralizing antibody titers after XBB.1.5 monovalent vaccine boost in healthcare workers and people with HIV

Matusali,

Mazzotta,

Meschi

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

Similar Limited Protection Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection in Vaccinated Individuals With HIV and Comparable Controls

Verburgh,

Boyd,

Schim van der Loeff

et al. 2024

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Background Little is known about the risk of SARS-CoV-2 Omicron infection in people with HIV (PWH) with vaccine-induced or hybrid immunity. We assessed the incidence of Omicron infection in 209 AGEhIV COVID-19 substudy participants with well-controlled HIV on ART and 280 comparable controls, who had received at least the primary vaccination series. Methods From September 2020 onward, participants were assessed every six months for SARS-CoV-2 infection incidence, as per SARS-CoV-2 nucleocapsid (N)-antibody assay or self-reported positive antigen- or PCR-test. Between January 1, 2022 and October 31, 2022, the cumulative incidence of Omicron infection and associated risk factors were estimated using a conditional risk-set Cox proportional hazards model. Results The cumulative incidence of a first Omicron infection was 58.3% by October 31, 2022, not significantly different between both groups. HIV-status was not independently associated with acquiring Omicron infection. Former and current smoking, as well as an increased predicted anti-S IgG titer were significantly associated with a lower risk of Omicron infection. The majority of infections were symptomatic, but none required hospitalization. Conclusions People with well-controlled HIV and controls in our cohort experienced a similarly high proportion of Omicron infections. A greater number of booster vaccinations significantly reduced the risk of infection. Clinical Trial Registration NCT01466582

show abstract

SARS-CoV-2 seroprevalence among people living with HIV in the German HIV-1 Seroconverter Cohort, 2020–2022

Hohn,

Meixenberger,

Volkwein

et al. 2024

BMC Infect Dis

View full text Add to dashboard Cite

Objectives People living with HIV (PLWH) are a risk group for severe symptoms and higher mortality during COVID-19. We analyzed the dynamic rise of SARS-CoV-2 seroprevalence induced by coinfections and vaccinations in PLWH in the first three years of the pandemic in Germany and compared it with corresponding data available for the general population. Methods Each month on average 93 blood samples from the German HIV-1 Seroconverter Cohort, a prospective longitudinal multicenter study that includes PLWH whose date of seroconversion is well defined, were received. The samples from 1569 PLWH were tested for the presence of anti-S1 and if positive, also for anti-N antibodies. Results In 2020 the number of anti-S1 positive cases/month was between 0.0 and 6.9% (average 1.6%). Since then the anti-S1 prevalence increased reaching already 35% (33/94) in May 2021. At that time 3.2% of the cases were also anti-N positive. In 2022 the average anti-S1 seroprevalence reached 97.5%. In the vaccination era a positive anti-N response was associated with a younger age and females were overrepresented among anti-S1/anti-N negative samples (assuming no vaccination or infection). Conclusions The average 1.6% anti-S1 seroprevalence in the cohort in 2020 was comparable to that in the general population (1.3%). The increase in anti-S1 seroprevalence in the first half of 2021 occurred slightly earlier. This increase was likely caused by the prioritization of PLWH at the early stage of the vaccination campaign and by infections during the third wave of the pandemic.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study

Cited by 3 publications

References 31 publications

JN.1 neutralizing antibody titers after XBB.1.5 monovalent vaccine boost in healthcare workers and people with HIV

JN.1 neutralizing antibody titers after XBB.1.5 monovalent vaccine boost in healthcare workers and people with HIV

Similar Limited Protection Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection in Vaccinated Individuals With HIV and Comparable Controls

SARS-CoV-2 seroprevalence among people living with HIV in the German HIV-1 Seroconverter Cohort, 2020–2022

Contact Info

Product

Resources

About